Joyce Thompson

2.9k total citations · 1 hit paper
35 papers, 1.6k citations indexed

About

Joyce Thompson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Joyce Thompson has authored 35 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 13 papers in Surgery. Recurrent topics in Joyce Thompson's work include Lung Cancer Treatments and Mutations (17 papers), Gastric Cancer Management and Outcomes (10 papers) and Esophageal Cancer Research and Treatment (9 papers). Joyce Thompson is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Gastric Cancer Management and Outcomes (10 papers) and Esophageal Cancer Research and Treatment (9 papers). Joyce Thompson collaborates with scholars based in United Kingdom, United States and Ireland. Joyce Thompson's co-authors include David Cunningham, Stephen Falk, A. Crellin, Ian Chau, Janet Dunn, F. Adab, David B. Smith, Juan W. Valle, Pauline Leonard and John P. Neoptolemos and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and The Journal of Urology.

In The Last Decade

Joyce Thompson

33 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

2009 602 citations David Cunningham, Ian Chau et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce Thompson United Kingdom	15	1.1k	968	397	358	270	35	1.6k
Masato Ozaka Japan	21	1.2k 1.1×	581 0.6×	358 0.9×	525 1.5×	188 0.7×	186	1.5k
Mauro Orlando United States	22	1.1k 0.9×	926 1.0×	177 0.4×	515 1.4×	249 0.9×	88	1.9k
Alain Gelibter Italy	22	974 0.9×	574 0.6×	333 0.8×	193 0.5×	332 1.2×	100	1.4k
Weimin Mao China	21	770 0.7×	980 1.0×	285 0.7×	546 1.5×	339 1.3×	91	1.7k
Muriel Debois Belgium	19	810 0.7×	907 0.9×	235 0.6×	306 0.9×	148 0.5×	39	1.6k
Daniel Swinson United Kingdom	17	562 0.5×	774 0.8×	233 0.6×	357 1.0×	245 0.9×	45	1.4k
Sebastiano Buti Italy	26	1.1k 1.0×	1.2k 1.2×	485 1.2×	369 1.0×	690 2.6×	210	2.2k
Menghua Dai China	21	1.1k 1.0×	394 0.4×	227 0.6×	570 1.6×	318 1.2×	107	1.5k
Usha Malhotra United States	21	785 0.7×	615 0.6×	153 0.4×	694 1.9×	370 1.4×	66	1.6k
Kostas Kalbakis Greece	28	1.8k 1.6×	806 0.8×	708 1.8×	232 0.6×	410 1.5×	90	2.1k

Countries citing papers authored by Joyce Thompson

Since Specialization

Citations

This map shows the geographic impact of Joyce Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Thompson more than expected).

Fields of papers citing papers by Joyce Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Thompson. The network helps show where Joyce Thompson may publish in the future.

Co-authorship network of co-authors of Joyce Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce Thompson. A scholar is included among the top collaborators of Joyce Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce Thompson. Joyce Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pascoe, Jennifer, Aimee Jackson, Charlotte Gaskell, et al.. (2021). Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH). BMC Cancer. 21(1). 800–800. 18 indexed citations

Ferry, David, Lucinda Billingham, Hugh Jarrett, et al.. (2017). Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer. 83. 302–312. 15 indexed citations

Haider, Abbas, et al.. (2017). P1.06-047 Management of Patients Aged over 70 Years with Newly Diagnosed Lung Cancer. Journal of Thoracic Oncology. 12(1). S694–S695. 1 indexed citations

Alderson, Derek, David Cunningham, Matthew Nankivell, et al.. (2017). Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. The Lancet Oncology. 18(9). 1249–1260. 149 indexed citations

Califano, Raffaele, Alastair Greystoke, Rohit Lal, Joyce Thompson, & Sanjay Popat. (2017). Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer. 111. 51–58. 15 indexed citations

Smyth, Elizabeth, Samuel Rowley, William Allum, et al.. (2016). A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology. 27. vi562–vi562. 2 indexed citations

Cunningham, David, Ruth E. Langley, Matthew Nankivell, et al.. (2015). LBA-03 Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). Annals of Oncology. 26. iv117–iv117. 7 indexed citations

Lal, Rohit, Gunnar Hillerdal, Riyaz Shah, et al.. (2015). Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 89(2). 154–160. 21 indexed citations

Petty, Russell, Åsa Dahle-Smith, Zosia Miedzybrodzka, et al.. (2014). Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. Journal of Clinical Oncology. 32(15_suppl). 4016–4016. 14 indexed citations

10.

Ford, Hugo, Andrea Marshall, Jonathan Wadsley, et al.. (2013). COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). LBA4–LBA4. 20 indexed citations

11.

Thompson, Joyce, et al.. (2013). 107 Emergency admissions of lung cancer patients to a West Midlands hospital: causes and outcomes. Lung Cancer. 79. S37–S37. 1 indexed citations

12.

Cook, Natalie, Andrea Marshall, Jane Blazeby, et al.. (2013). Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.. Journal of Clinical Oncology. 31(15_suppl). 4023–4023. 9 indexed citations

13.

Natale, Ronald B., Sumitra Thongprasert, F. Anthony Greco, et al.. (2011). Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(8). 1059–1066. 244 indexed citations

14.

Ferry, D., Lucinda Billingham, Hugh Jarrett, et al.. (2011). S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC. Thorax. 66(Suppl 4). A41–A41. 8 indexed citations

15.

Cunningham, David, Ian Chau, Deborah Stocken, et al.. (2009). Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology. 27(33). 5513–5518. 602 indexed citations breakdown →

16.

Goss, Glenwood, David Ferry, Scott A. Laurie, et al.. (2007). B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP). Journal of Thoracic Oncology. 2(8). S340–S340. 12 indexed citations

17.

Richards, Jon, A. Y. Bedikian, René González, et al.. (2005). High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. Journal of Clinical Oncology. 23(16_suppl). 7543–7543. 5 indexed citations

18.

Stadler, Walter M., et al.. (2005). A phase II study of depsipeptide (Dep) in patients (pts) with metastatic renal cell cancer (RCC). Journal of Clinical Oncology. 23(16_suppl). 4669–4669. 3 indexed citations

19.

Stevenson, G T & Joyce Thompson. (1988). Idiotypes and anti‐idiotypes in myeloma. Hematological Oncology. 6(2). 103–106. 4 indexed citations

20.

Thompson, Joyce & Mary Whittaker. (1966). A Study of the Pseudocholinesterase in 78 Cases of Apnoea Following Suxamethonium. Human Heredity. 16(3). 209–222. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact